Bibliography
- DECLERCK PJ, JUHAN-VAGUE I, FELEZ J, WIMAN B: Pathophysiology of fibrinolysis. j Intern. Med. (1994) 236:425–432.
- VAN MEIJER M, PANNEKOEK H: Structure of plasminogen activator inhibitor-1 (PAT-1) and its function in fibrinolysis. An update. Fibrinolysis (1995) 9:263–276.
- POTEMPA J, KORZUS E, TRAVIS J: The serpin superfamily of protease inhibitors: structure, function and regulation. I Biol. Chem. (1994) 269:15957–15960.
- DAWSON S, HENNEY A: The status of PAT-1 as a risk factor for arterial and thrombotic disease: a review. Artherosclerosis (1992) 95:105–117.
- AZNAR J, ESTELLES A: Role of plasminogen activator inhibitor Type 1 in the pathogenesis of coronary artery diseases. Haemostasis (1994) 24:243–251.
- ERIKSON LA, FICI GJ, LUND JE, BOYLE TP, POLITES HG, MAROTTI KR: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature (1990) 346:74–76.
- BIEMOND BJ, LEVI M, CORONEL R, JANSE MJ, TEN CATE JW, PANNEKOEK H: Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor Type 1-neutralizing monoclonal antibody. Circulation (1995) 91:1175–1181.
- PAPPOT H, GARDSVOLL H, ROMER J et al.: Plasminogen activator inhibitor Type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler (1995) 376.259–267.
- BAJOU K, NOM, A, GERARD RD etal.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. (1998) 4:923–928.
- •An excellent paper demonstrating that host-produced PAT-1 is essential for cancer cell invasion and angiogenesis.
- TSUCHIYA H, KATSUO S, MATSUDA E et al.: The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen. Diagn. Pathol. (1995) 141:41–48.
- SANCHO E, DECLERCK PJ, PRICE NC,KELLY SM, BOOTH NA: Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate and cleaved forms. Biochemistry (1995) 34:1064–1069.
- EITZMAN DT, FAY WE LAWRENCE DA et al.: Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. j Clin. Invest. (1995) 95:2416–2420.
- FOLKES A, ROE MB, SOHAL S et al:Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1. Bioorg. Med. Chem. Lett. (2001) 11:2589–2592.
- FOLKES A, BROWN SD, CANNE LE et al: Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1. Bioorg. Med. Chem. Lett. (2002) 12:1063–1006
- EGELUND A, EINHOLM A, PEDERSEN K et al: A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization. I Biol. Chem (2001) 276(16):13077–13086.
- BJORQUIST P, EHNEBOM J, INGHARDT T etal.: Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor Type 1 by site directed mutagenesis. Biochemistry (1998) 37:1227–1234.
- •An important paper describing site-directed mutagenesis to help identify a binding site for a low molecular weight inhibitor of PAT-i.
- FRIEDERICH PW, LEVI M, BIEMOND W et al.: Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post-thrombolysis thrombus growth in rabbits. Circulation (1997) 96:916–921.
- •The demonstration that a low molecular weight inhibitor of PAT-1 can enhance fibrinolysis and reduce thrombus grown in vivo.